Improvement of muscle strength in a mouse model for congenital myopathy treated with HDAC and DNA methyltransferase inhibitors

Improvement of muscle strength in a mouse model for congenital myopathy treated with HDAC and DNA methyltransferase inhibitors

To date there are no therapies for patients with congenital myopathies, muscle disorders causing poor quality of life of affected individuals. In approximately 30% of the cases, patients with congenital myopathies carry either dominant or recessive mutations in the ryanodine receptor 1 (RYR1) gene;...

Full description

Bibliographic Details
Main Authors: Alexis Ruiz, Sofia Benucci, Urs Duthaler, Christoph Bachmann, Martina Franchini, Faiza Noreen, Laura Pietrangelo, Feliciano Protasi, Susan Treves, Francesco Zorzato
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2022-03-01
Series:eLife
Subjects:
ryanodine receptor mutations
congenital myopathy
treatment
muscle function
epigenetic enzymes
Online Access:https://elifesciences.org/articles/73718

Internet

https://elifesciences.org/articles/73718

Similar Items